correlations between her2 alterations and pd-l1 expression in bladder cancer
Published 7 months ago • 163 plays • Length 2:41Download video MP4
Download video MP3
Similar videos
-
2:50
concordance of different pd-l1 assays: expression in bladder and kidney cancer
-
4:51
dr annu rajpurohit: her2 & pd-l1 in advanced bladder cancer: insights from crs 2024 | crsf
-
0:36
unlocking her2: key insights into bladder cancer prognosis
-
1:30
hhla2 vs pd-l1 expression in urothelial tumors
-
51:24
her2 and her3 alterations as therapeutic targets of increasing significance in solid tumors
-
1:25
her2-low as a separate entity for defining her2 bc and its prognostic and biological significance
-
0:52
what are the latest biomarkers for urothelial carcinoma?
-
21:59
palb2
-
10:07
importance of biomarkers when evaluating heterogeneity in her2 metastatic bc
-
1:37
maintenance lapatinib after first-line chemotherapy in her1/2-positive metastatic bladder cancer
-
1:41
scientists propose a breast cancer drug for some bladder cancer patients
-
1:40
phase 2/3 trial of maintenance lapatinib for her1/2-positive metastatic bladder cancer
-
2:54
reviewing a case of her2 inflammatory breast cancer
-
1:19
dr. lin on the treatment landscape in her2 metastatic breast cancer
-
1:07:30
role of her2-directed therapy in the treatment of her2-expressing urothelial bladder cancer — par...
-
0:45
dr. hamilton on using pcr to classify risk in her2 breast cancer
-
1:09
results of the combined inhibition of ido1 and pd-l1 in locally advanced or metastatic solid tumors
-
3:24
her2 testing and clinical decision making in gastroesophageal adenocarcinoma guideline
-
1:59
sacituzumab govitecan and nktr-214 plus nivolumab for bladder cancer